Sun, June 21, 2026
AUS Edition NZ Edition UK Edition
CA Edition USA Edition IND Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. RPRX
Healthcare
Facebook Twitter Linkedin

Royalty Pharma Plc (NASDAQ:RPRX)

52.96 USD

-0.740 1.378%
Last Updated at: 2026-06-18T20:52:00Z

Royalty Pharma Plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

110 East 59th Street, New York, NY, United States, 10022

212 883 0200

https://www.royaltypharma.com

Key Executives

Sr. No. Name Title Year Born
1. Mr. Pablo Gerardo Legorreta Founder, Chairman & CEO 1964
2. Mr. Terrance P. Coyne Exec. VP & CFO NA
3. Mr. George Wingate Lloyd Exec. VP of Investments & Chief Legal Officer 1959
4. Mr. Christopher Hite Vice Chairman & Exec. VP 1967
5. Dr. Marshall Urist M.D., Ph.D. Exec. VP and Head of Research & Investments NA
6. Mr. Arthur R. McGivern J.D. Exec. VP of Investments & Gen. Counsel NA
7. Ms. Kristin Stafford Sr. VP & Chief Accounting Officer NA
8. Dr. James Folmar Reddoch Ph.D. Exec. VP of Investments & Chief Scientific Officer 1970
9. Mr. George Grofik C.F.A., CPA Sr. VP and Head of Investor Relations & Communications NA
10. Ms. Alessandra Sassun VP & Head of Human Capital NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.330 0.758% 43.45 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 0.000 0.000% 43 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 -7.360 1.604% 462.17 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 +2.010 0.331% 612.07 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Income Before Tax 230.064M 1241.201M 1702M 2461.419M 1517.855M
Minority Interest 187.232M 621.473M 726.914M 35.883M 63.865M
Net Income 42.832M 478.754M 555M 2348.535M 1377.729M
Selling General Administrative 227.303M 182.826M 182M 103.439M 61.906M
Gross Profit 2231.545M 2266.467M 2033.889M 1814.254M 1658.934M
Reconciled Depreciation 5.67M 22.996M 23.058M 23.924M 33.267M
Ebit 977.499M 1430.715M 1595M 2623.176M 1380.346M
Ebitda 983.169M 1482.078M 1882M 2637.305M 1413.613M
Depreciation And Amortization 5.67M 51.363M 287M 14.129M 33.267M
Operating Income 977.499M 1430.715M 1595M 2623.176M 1364.446M
Other Operating Expenses 1314.323M 858.748M 527M -808.922M 430.448M
Interest Expense 187.961M 166.142M 157M 268.573M 279.956M
Tax Provision 0M 0M 0M 0M 0M
Interest Income 78.335M 53.535M 28.379M 22.329M 24.441M
Net Interest Income -109.626M -112.607M -157M -246.244M -255.515M
Income Tax Expense 187.232M 762.447M 1147M 349.333M 433.365M
Total Revenue 2237.215M 2289.463M 2122M 1814.254M 1794.894M
Total Operating Expenses 1314.323M 858.748M 527M -808.922M 430.448M
Cost Of Revenue 5.67M 22.996M 88.111M - 135.96M
Total Other Income Expense Net -747.435M -189.514M 107M -161.757M 408.924M
Net Income From Continuing Ops 230.064M 1241.201M 1689.081M 2461.419M 1517.855M
Net Income Applicable To Common Shares 42.832M 619.728M 975.04M 2348.535M 1377.729M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2023 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Total Assets 16381.851M 16813.466M 17515.865M 21097.036M 12449.895M
Intangible Assets 1.778M - 5.67M 28.666M 51.724M
Other Current Assets 3.798M 90.52M 6.631M 8.596M 0.092M
Total Liab 6297.562M 7288.093M 7267.32M 6124M 6308.457M
Total Stockholder Equity 6526.497M 5628.15M 5776.594M 9896M 6105.555M
Other Current Liab 146.212M 161.365M 165.63M 297.112M 9.215M
Common Stock 0.045M 0.107M 0.106M 0.102M 3282.516M
Capital Stock 0.108M 0.107M 0.106M 0.102M 3282.516M
Retained Earnings 2517.583M 1964.689M 2255.179M 1920.635M 2825.212M
Good Will - - - - -
Other Assets - 13508.235M 13722.39M 5076.75M 10930.002M
Cash 477.01M 1710.751M 1541.048M 1009M 283.682M
Cash And Equivalents - - - - -
Total Current Liabilities 161.377M 1166.783M 171.25M 307.887M 333.417M
Current Deferred Revenue - - - - 31.041M
Net Debt 5658.275M 5405.571M 5555.022M 4807.584M 5954.44M
Short Term Debt - 997.512M -6891.67M 281.984M 281.984M
Short Long Term Debt - 997.512M - - 281.984M
Short Long Term Debt Total 6135.285M 7116.322M 7096.07M 5816.584M 6238.122M
Other Stockholder Equity 4008.806M 3663.354M 3504.818M 7940.868M -4.266M
Property Plant Equipment - - - - -
Total Current Assets 1274.193M 2554.908M 2878.211M 2696.898M 832.072M
Long Term Investments 15101.136M 14116.581M 14358.039M 12972.875M 11478.149M
Short Term Investments 18.3M 717.04M 1262.223M 983M 509.532M
Net Receivables 775.085M 36.597M 68.309M 39.166M 38.766M
Long Term Debt 6135.285M 6118.81M 7096.07M 5816.584M 5956.138M
Inventory - - - 657.136M -
Accounts Payable 15.165M 7.906M 5.62M 10.775M 11.177M
Accumulated Other Comprehensive Income 0.063M - 16.491M 34.395M 2.093M
Non Currrent Assets Other 14093.399M 29.629M 4.145M 28.597M 87.95M
Non Current Assets Total 15107.658M 14258.558M 14637.654M 13323.388M 11617.823M
Capital Lease Obligations - - - - -
Long Term Debt Total - 6118.81M 7096.07M 5816.584M 5956.138M

Cash Flow

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Investments -1152.794M -1832.503M -3094.16M -2116.142M 573.017M
Total Cashflows From Investing Activities -1029.421M -1870.28M -2759.32M -2153.625M 303.424M
Total Cash From Financing Activities -944.856M 385.112M 1487M -1191.626M -1379.101M
Net Income 230.064M 1241.201M 1701.954M 2461.419M 1517.855M
Change In Cash 169.703M 532.368M 763M -1640.529M 542.64M
Begin Period Cash Flow 1541.048M 1008.68M 246M 1924.211M 1381.571M
End Period Cash Flow 1710.751M 1541.048M 1009M 283.682M 1924.211M
Total Cash From Operating Activities 2143.98M 2017.536M 2034.629M 1667.239M 1618.317M
Depreciation 5.67M 22.996M 23.058M 23.924M 33.267M
Other Cashflows From Investing Activities 123.373M -37.777M 334.84M -258.84M -258.84M
Dividends Paid -333.322M -285.184M -397M -739.276M 814.359M
Change To Inventory - - - - -
Sale Purchase Of Stock -144.115M -479.604M 11891M - 0M
Other Cashflows From Financing Activities -611.534M 670.296M -706M -158.35M -270.742M
Capital Expenditures 2041.152M 0.523M 2197M 1721.291M 269.593M
Change In Working Capital 32.662M -16.322M -1884.009M -1673.508M -1562.379M
Other Non Cash Items 1873.414M 2289.581M 2122.708M 855.404M 1629.574M
Free Cash Flow 4185.132M 2018.059M 4231.629M 1667.239M 1887.91M

Funds

Sr. No. Name Purchased On Shares
1. Vanguard Total Stock Mkt Idx Inv 2 years ago 11821574
2. Vanguard Mid Cap Index Institutional 2 years ago 8269053
3. Morgan Stanley Growth SMA 2 years ago 7427443
4. Morgan Stanley Growth 2 years ago 7427443
5. Morgan Stanley Inst Growth I 2 years ago 7427443
6. MS INVF US Advantage I 2 years ago 6670795
7. Fidelity Contrafund 2 years ago 6302430
8. Vanguard Institutional Extnd Mkt Idx Tr 2 years ago 5742281
9. MS INVF US Growth I 2 years ago 5048154
10. Vanguard Value Index Inv 2 years ago 3168312
11. Swedbank Robur Transfer 70 2 years ago 2967500
12. Fidelity Contrafund Commingled Pl O 2 years ago 2707732
13. Vanguard Mid-Cap Value ETF 2 years ago 2670608
14. Fidelity Select Health Care 2 years ago 2650000
15. Swedbank Robur Aktiefond Pension 2 years ago 2600700
16. JPMorgan Growth Advantage A 2 years ago 2555566
17. Fidelity Balanced 2 years ago 2541900
18. Transamerica Capital Growth A 2 years ago 2300501
19. State St Russell Sm/Mid Cp® Indx NL Cl C 2 years ago 2284524
20. Fidelity Extended Market Index 2 years ago 2208471

Institutions

Sr. No. Name Purchased On Shares
1. Morgan Stanley - Brokerage Accounts 2 years ago 46354266
2. Vanguard Group Inc 2 years ago 37699682
3. FMR Inc 2 years ago 31583929
4. BlackRock Inc 2 years ago 21459462
5. Baillie Gifford & Co Limited. 2 years ago 16662792
6. Viking Global Investors LP 2 years ago 11485547
7. Adage Capital Partners Gp LLC 2 years ago 10816931
8. State Street Corporation 2 years ago 8873550
9. JPMorgan Chase & Co 2 years ago 8700319
10. Geode Capital Management, LLC 2 years ago 6367611
11. Goldman Sachs Group Inc 2 years ago 5739092
12. Unisphere Establishment 2 years ago 5000000
13. Millennium Management LLC 2 years ago 4667146
14. NORGES BANK 2 years ago 4262736
15. Amundi 2 years ago 3692896
16. Siguler Guff Advisers, LLC 2 years ago 3391754
17. Legal & General Group PLC 2 years ago 2919320
18. Northern Trust Corp 2 years ago 2634175
19. Suvretta Capital Management, LLC 2 years ago 2250361
20. California Public Employees Retrmnt Sys 2 years ago 2134904
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Sponsored Articles

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App